文献速递胸部肿瘤

BRG1缺陷型非小细胞肺癌的临床病理特征

Clinicopathologic Characteristics of BRG1-Deficient NSCLC.
PubMed 文献 · J Thorac Oncol · 2020-01-24

该研究回顾性分析两个数据集中SMARCA4突变型NSCLC的患病率及临床病理特征,发现BRG1缺陷富集于截短型SMARCA4突变,且该分子亚组一线治疗预后差。

要点

  • SMARCA4突变在NSCLC中占9%-11%,截短突变占三分之一以上。
  • 截短型SMARCA4突变NSCLC中84%缺乏BRG1表达。
  • BRG1缺陷型NSCLC一线化疗或化疗联合免疫中位PFS仅约35-38天。

核心结论

  • BRG1缺陷富集于携带截短型SMARCA4突变的NSCLC,该分子亚组临床预后差。

研究设计与样本

  • 回顾性分析Massachusetts General Hospital和Foundation Medicine两个数据集的NSCLC患者,评估SMARCA4突变患病率及临床病理特征,并用免疫组化检测BRG1表达。

主要发现

  • 机构数据集SMARCA4基因组改变占9%(117/1422),Foundation Medicine数据集占11%(3188/27281)。
  • 两个队列中截短突变占SMARCA4改变的三分之一以上。
  • 评估的31例截短SMARCA4突变NSCLC中84%(26/31)缺乏BRG1表达。
  • BRG1表达缺陷主要见于共现KRAS、TP53、KEAP1和STK11突变的腺癌。

关键数值与推荐

  • 接受一线铂类双药化疗的BRG1缺陷型NSCLC患者(n=11)中位无进展生存期为38天。
  • 接受化疗联合免疫治疗的BRG1缺陷型NSCLC患者(n=5)中位无进展生存期为35天。

临床怎么用

  • 对NSCLC进行SMARCA4突变检测及BRG1免疫组化有助于识别预后差的BRG1缺陷亚组。
  • BRG1缺陷型NSCLC患者一线化疗或化疗联合免疫疗效欠佳,需探索针对其治疗脆弱性的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation increases tumor aggressiveness but enhances sensitivity to drugs that target oxidative phosphorylation and inhibit SMARCA2, EZH2, CDK4, or CDK6. To facilitate translation of preclinical findings into clinical studies exploiting these therapeutic vulnerabilities, we assessed the clinical features of patients with tumors harboring BRG1-inactivating mutations. METHODS: Data sets from Massachusetts General Hospital and Foundation Medicine were reviewed to determine the prevalence of SMARCA4-mutant NSCLC and describe its clinicopathologic characteristics. BRG1 expression was evaluated by immunohistochemistry and correlated with SMARCA4 mutations. Treatment outcomes were retrospectively assessed. RESULTS: We detected SMARCA4 genomic alterations in 9% (n = 117 of 1422) and 11% (n = 3188 of 27,281) of NSCLCs in the institutional and Foundation Medicine data sets, respectively. In both cohorts, truncating mutations comprised over one-third of SMARCA4 alterations. Twenty-nine of 64 SMARCA4-mutant NSCLCs (45%) assessed for BRG1 expression reported loss of expression, most (90%) of which had truncating SMARCA4 mutations. Overall, 84% (n = 26 of 31) of evaluated NSCLCs with truncating SMARCA4 mutations lacked BRG1 expression. Deficient BRG1 expression was predominantly detected in adenocarcinomas with co-occurring mutations in KRAS, TP53, KEAP1, and STK11. Among patients with BRG1-deficient NSCLC who received first-line platinum doublet chemotherapy (n = 11) or chemotherapy plus immunotherapy (n = 5), median progression-free survival was 38 days and 35 days, respectively. CONCLUSIONS: BRG1 deficiency is enriched in NSCLCs with truncating SMARCA4 mutations. Clinical outcomes are poor in this molecular subgroup, highlighting the importance of developing novel strategies to target unique vulnerabilities associated with the BRG1-deficient state.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Schrock AB, Kem M, et al. Clinicopathologic Characteristics of BRG1-Deficient NSCLC. J Thorac Oncol. 2020. PMID: 31988001. doi:10.1016/j.jtho.2020.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。